Portal Hypertension: Causes, Diagnosis and Treatment in Liver Disease

Portal hypertension is one of the most consequential complications of chronic liver disease, defined as an elevated hepatic venous pressure gradient (HVPG) above 5 mmHg. When HVPG exceeds 10 mmHg — termed clinically significant portal hypertension (CSPH) — the risk of decompensation events including variceal haemorrhage, ascites, and hepatic encephalopathy rises sharply. As a hepatologist managing advanced liver disease daily at Gleneagles Hospital Mumbai, I see the full clinical spectrum of portal hypertension, from incidental discovery on imaging to acute variceal bleeding requiring emergency intervention.

What Causes Portal Hypertension?

The portal vein carries blood from the gut, spleen, and pancreas to the liver. When resistance to this flow increases — most commonly from cirrhosis — pressure backs up across the portal system. The causes are classified by the site of obstruction:

• Prehepatic: Portal vein thrombosis, splenic vein thrombosis
• Intrahepatic (sinusoidal): Cirrhosis from any cause — this accounts for over 90% of cases in clinical practice. Common aetiologies include alcohol-related liver disease (ALD), metabolic-associated steatotic liver disease (MASLD), chronic hepatitis B and C, autoimmune hepatitis, and primary biliary cholangitis.
• Intrahepatic (pre-sinusoidal): Schistosomiasis, nodular regenerative hyperplasia, congenital hepatic fibrosis
• Post-hepatic: Budd-Chiari syndrome, right heart failure, constrictive pericarditis

In India, non-cirrhotic causes — particularly non-cirrhotic portal fibrosis (NCPF) and extrahepatic portal vein obstruction (EHPVO) — account for a significant proportion of portal hypertension cases, particularly in younger patients presenting with splenomegaly and variceal bleeding.

How is Portal Hypertension Diagnosed?

The gold standard for measuring portal pressure is the hepatic venous pressure gradient (HVPG), obtained by hepatic vein catheterisation. An HVPG ≥10 mmHg defines CSPH and ≥12 mmHg is the threshold above which variceal haemorrhage can occur.

In routine clinical practice, non-invasive markers have largely replaced HVPG for initial stratification:

• Liver stiffness measurement (LSM) by transient elastography (FibroScan): LSM ≥25 kPa reliably predicts CSPH in MASLD; ≥15 kPa in alcohol-related and viral cirrhosis. The Baveno VII consensus (2021) incorporated LSM-based algorithms for CSPH diagnosis.
• Platelet count + LSM (Baveno VII criteria): Platelets >150×10⁹/L + LSM <20 kPa rules out high-risk varices with high accuracy — sparing patients unnecessary endoscopy.
• Upper GI endoscopy: Detects oesophageal and gastric varices, portal hypertensive gastropathy. Recommended at diagnosis of cirrhosis if LSM/platelet criteria are not met.
• Imaging: Ultrasound with Doppler evaluates portal vein diameter (>13 mm suggestive), flow direction, splenomegaly, and collaterals. CT portal venography maps the anatomy when intervention is planned.

Complications of Portal Hypertension

Portal hypertension is the driving force behind all major decompensating events in cirrhosis. Understanding the pathway matters for patient counselling and treatment planning:

Varices and Variceal Haemorrhage

Portosystemic collaterals form as blood seeks alternative pathways. Oesophageal varices develop in 50% of cirrhotics; large varices (>5 mm) and red wale signs on endoscopy predict haemorrhage risk. Acute variceal bleeding carries a 6-week mortality of 15–20% in compensated cirrhosis and up to 50% in decompensated patients (Child-Pugh C). Management follows the Baveno VII and APASL 2022 guidelines: early vasoactive therapy (terlipressin or somatostatin analogues), endoscopic band ligation (EBL), antibiotic prophylaxis (ceftriaxone 1g/day × 7 days), and early TIPS in high-risk patients (Child-Pugh B with active bleeding, or Child-Pugh C score 10–13).

Ascites

Ascites is the most common complication of cirrhosis, developing in 50% of patients within 10 years of diagnosis. CSPH drives splanchnic vasodilation → sodium retention → fluid accumulation. First-line management: sodium restriction (88 mmol/day), spironolactone ± furosemide. Refractory ascites — defined as failure to respond to maximal doses or recurrence within 4 weeks — requires large-volume paracentesis with albumin replacement (8g/L drained), or TIPS in selected patients.

Hepatic Encephalopathy

Portosystemic shunting bypasses hepatic ammonia detoxification, precipitating hepatic encephalopathy (HE). HE significantly worsens prognosis and quality of life. Lactulose and rifaximin remain the cornerstones of management — a topic I discuss in detail in my article on hepatic encephalopathy treatment.

Spontaneous Bacterial Peritonitis (SBP)

SBP — infection of ascitic fluid without an intra-abdominal source — occurs in 10–30% of hospitalised cirrhotics with ascites. It carries a 20% in-hospital mortality and a 1-year mortality exceeding 60% without liver transplantation. Diagnosis requires ascitic PMN count ≥250 cells/mm³. Treatment: cefotaxime 2g IV 8-hourly × 5 days + albumin 1.5 g/kg on day 1 and 1 g/kg on day 3 to prevent hepatorenal syndrome.

Treatment of Portal Hypertension

Non-selective Beta-Blockers (NSBBs)

NSBBs — propranolol, nadolol, or carvedilol — reduce portal pressure by decreasing cardiac output and splanchnic vasoconstriction. Carvedilol (6.25–12.5 mg/day) is more effective at reducing HVPG than traditional NSBBs and is preferred in patients with CSPH who have not bled. Target: resting heart rate 55–60 bpm. NSBBs reduce the risk of first variceal haemorrhage by ~50% and are recommended for primary prophylaxis in patients with medium or large varices (EASL 2018, Baveno VII 2021).

Endoscopic Band Ligation (EBL)

EBL is equally effective to NSBBs for primary prophylaxis and is preferred when NSBBs are contraindicated or not tolerated. For secondary prophylaxis (prevention of rebleeding), combination EBL + NSBB is superior to either alone — reducing rebleeding from ~40% to ~15–20%. EBL sessions are repeated every 2–4 weeks until variceal obliteration, then surveillance endoscopy every 3–6 months.

Transjugular Intrahepatic Portosystemic Shunt (TIPS)

TIPS creates a stent between the hepatic vein and portal vein, mechanically decompressing the portal system. Indications include refractory ascites, recurrent variceal haemorrhage despite EBL + NSBB, and acute variceal bleeding in Child-Pugh B/C patients (pre-emptive TIPS within 72 hours). Covered stents (ePTFE) have dramatically improved TIPS patency. Contraindications: severe hepatic encephalopathy, heart failure, polycystic liver disease, uncontrolled infection.

Liver Transplantation

Liver transplantation is the definitive treatment for portal hypertension in cirrhosis — it removes the diseased liver, eliminates the underlying resistance, and restores normal portal haemodynamics. Transplant evaluation should be initiated when MELD score exceeds 15 or at the first episode of decompensation. I routinely manage international patients seeking liver transplantation in India, where outcomes at leading centres are equivalent to Western programmes at a fraction of the cost. For patients from the UK, UAE, or Canada, see my international patients page for guidance on the process.

Frequently Asked Questions About Portal Hypertension

Can portal hypertension be reversed?

In early-stage liver disease — before cirrhosis is established — treating the underlying cause (antiviral therapy for hepatitis B or C, alcohol abstinence, weight loss in MASLD) can meaningfully reduce portal pressure and even reverse fibrosis. Once advanced cirrhosis is present, reversal is less likely though HVPG can still improve with treatment. Only liver transplantation fully normalises portal haemodynamics in established cirrhosis.

What is a dangerous portal vein pressure?

Normal HVPG is 1–5 mmHg. Above 10 mmHg (CSPH), decompensation risk rises. Above 12 mmHg, varices can bleed. An HVPG ≥20 mmHg at the time of acute variceal bleeding predicts treatment failure and very high mortality — these patients are candidates for emergency TIPS.

Is portal hypertension the same as high blood pressure?

No. Portal hypertension refers specifically to elevated pressure in the portal venous system — it has no direct relationship to systemic arterial blood pressure (hypertension). Many patients with portal hypertension actually have low systemic blood pressure due to splanchnic vasodilation.

How is portal hypertension monitored without a liver biopsy?

Non-invasive monitoring tools include FibroScan (transient elastography), platelet count trends, spleen size on ultrasound, and von Willebrand factor/platelet ratio (VITRO score). Serial FibroScan every 6–12 months in cirrhotic patients allows tracking of disease progression or regression without repeated biopsies.

---

Dr. Chetan Kalal is a DM Hepatologist (ILBS, New Delhi) and liver transplant physician at Gleneagles Hospital, Mumbai. He is the first DM Hepatologist of Maharashtra and a recipient of the AASLD Foundation Award. For consultations — including telemedicine for international patients — contact the clinic.